Current Methods for the Assessment and Management of Taxane-Related Neuropathy

Ellen M. Lavoie Smith, PhD, ANP-BC, AOCN®

Taxane-induced peripheral neuropathy (TIPN) significantly compromises the quality of life of breast cancer survivors. TIPN is an underrecognized problem because of continued reliance on suboptimal assessment approaches. Emerging empirical evidence suggests that more reliable, valid, sensitive, and clinically feasible TIPN measurement approaches should be used to quantify TIPN in clinical and research settings (Cavaletti et al., 2010; Griffith, Merkies, Hill, & Cornblath, 2010). Oncology nurses know that TIPN poses significant problems for patients with breast cancer. Although most oncology nurses are well versed regarding TIPN signs, symptoms, and related adverse outcomes, this knowledge does not necessarily translate into knowing what to do about it. Measurement approaches should include objective assessment of peripheral neuropathy signs and symptoms using history taking and simple physical examination approaches. TIPN signs and symptoms can be quantified using a composite measure such as the revised and shortened Total Neuropathy Score (TNS) (Chaudhry, Rowinsky, Sartorius, Donehower, & Cornblath, 1994; Cornblath et al., 1999; Lavoie Smith, Cohen, Pett, & Beck, 2011; Smith, Beck, & Cohen, 2008; Smith, Cohen, Pett, & Beck, 2010). In addition, patient-reported outcome measures should be used to assess the patient’s experience and the short 11-item Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity subscale often is used because of its excellent psychometric properties (Griffith et al., 2010). To date, duloxetine is the only pharmacologic intervention tested via a large phase III trial that has been shown to be effective in diminishing TIPN-related pain. Future testing of additional pharmacologic and nonpharmacologic interventions is needed.

Pathophysiology

Taxane chemotherapy (paclitaxel, docetaxel, and nab-paclitaxel) has led to significant improvements in breast cancer survival in patients with metastatic breast cancer. However, in addition to killing cancer cells, taxanes cause unwanted damage to the nerve cell axon and surrounding myelin sheath and the cell body within the dorsal root ganglion (Argyriou, Koltzenburg, Polychronopoulos, & Beck, 2011). In addition, patient-reported outcome measures should be used to assess the patient’s experience and the short 11-item Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity subscale often is used because of its excellent psychometric properties (Griffith et al., 2010). To date, duloxetine is the only pharmacologic intervention tested via a large phase III trial that has been shown to be effective in diminishing TIPN-related pain. Future testing of additional pharmacologic and nonpharmacologic interventions is needed.
Although the precise TIPN pathophysiologic mechanism is unknown, taxanes are believed to exert their neurotoxic effects on peripheral nerves by stabilizing the microtubule system critical for mitosis and intracellular transport of proteins and other substances between the axon and the cell body (Argyriou et al., 2008; Carlson & Ocean, 2011; Swain & Arezzo, 2008; Theiss & Meller, 2000). Once the microtubule transport system becomes damaged, the cell undergoes apoptosis (programmed cellular death) (Carlson & Ocean, 2011). Mitochondrial swelling, damage to peripheral nerve support structures, and various immune mechanisms have been implicated in the development of painful TIPN (Flatters & Bennett, 2006; Peters et al., 2007; Polomano, Mannes, Clark, & Bennett, 2001; Siau, Xiao, & Bennett, 2006; Zheng, Xiao, & Bennett, 2011). In addition, the Cremophor® EL (polyoxyethylated castor oil; now renamed as Koliphor® EL) solvent used to formulate paclitaxel may contribute to TIPN, but a definitive causal relationship has not been established (Authier, Gillet, Fialip, Eschalier, & Coudore, 2000; Gradishar et al., 2005; Hausheer, Schilsky, Bain, Berghorn, & Lieberman, 2006; Swain & Arezzo, 2008).

**Clinical Manifestations**

TIPN is generally described as a symmetrical “dying back” phenomenon, meaning that the tips of the longest nerves are affected first. That explains why most patients initially report TIPN symptoms in their toes. As an individual receives higher cumulative taxane doses, symptoms extend up the feet to the ankles and lower legs and eventually appear in the fingertips, hands, wrists, and arms. Although all peripheral nerve types (sensory, motor, and autonomic) can be damaged as a result of taxane therapy, large, myelinated sensory nerve fibers are the most vulnerable (Argyriou et al., 2008; Carlson & Ocean, 2011). Common sensory symptoms include numbness, tingling, electric shock-like sensations, neuropathic pain, and impaired balance from diminished plantar sensation and resultant altered proprioception (Kuroi & Shimozuma, 2004; Swain & Arezzo, 2008; Wickham, 2007). Patients typically compensate for balance impairment by broadening their gate and using visual, rather than sensory, clues when monitoring foot placement. Impaired sensation in the fingertips can compromise the ability to manipulate small objects, button or zip clothing, or perform other daily tasks. Patients occasionally report mechanical or temperature-induced injuries. Those injuries occur when TIPN-related numbness impairs the patient’s ability to sense sharp objects or extremely hot or cold temperatures. Occurring in about 25%–30% of patients, painful peripheral neuropathy can be particularly distressing (Loprinzi et al., 2011; Smith et al., 2010). One type of neuropathy-related pain, allodynia, occurs when pain results from nonpainful stimuli. For example, patients may report pain when bed sheets touch their feet or when attempting to wear common clothing items, such as socks, shoes, or gloves.

TIPN signs include diminished or absent reflexes as well as altered vibration, temperature, and pin sensibility. Those TIPN signs are detectable only via physical examination and may appear earlier than subjective symptoms. As such, patients may not notice these TIPN signs before a clinician detects the deficit during a physical examination. This emphasizes the importance of the clinical examination because detection of preclinical signs (occurring early and before the emergence of patient-reported symptoms) can provide evidence that TIPN is worsening before the patient is aware that a problem exists. Although less common, upper and lower extremity motor weakness can occur. Motor weakness is typically evidenced when the patient is, for example, unable to turn on or off sink faucets, reports frequent tripping and falls, has difficulty managing a vehicle’s gas and brake pedals, or when a foot drop becomes noticeable. Autonomic neuropathy symptoms (e.g., constipation, erectile dysfunction, orthostatic hypotension, urinary retention) also occur, albeit infrequently. Autonomic symptoms are more difficult to attribute to TIPN because of the presence of other comorbid conditions or concurrent media
tions that can lead to similar problems. Lastly, paclitaxel acute pain syndrome is characterized by moderate to severe pain in the back, hips, shoulders, thighs, and legs occurring during the first week following paclitaxel administration (Loprinzi et al., 2011). The symptoms of paclitaxel acute pain syndrome have been described as affecting the muscles and joints, but evidence suggests that this pain is instead because of taxane-related nerve injury (Loprinzi et al., 2011).

**Measurement**

TIPN incidence data from breast cancer phase III studies are quite variable. Table 1 presents data demonstrating that TIPN incidence rates reported in phase III trials of metastatic and adjuvant populations conducted since the mid-2000s range from 8%–83%. The majority of patients with metastatic breast cancer included in these trials had previously received a neurotoxic agent. Unless otherwise indicated, TIPN was quantified using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE) (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm). Higher TIPN incidence and severity are generally associated with more frequent taxane administration and higher cumulative dosages. However, incidence rates vary greatly across studies when comparisons are made of TIPN caused by the same taxane with the same dose and treatment schedules. What might explain these discrepancies? The wide range in reported incidence is partially attributable to the presence or absence of various factors known to influence the risk of developing TIPN, such as taxane type, the dose administered (M³), cumulative dosage, and dose density, as well as demographic, genetic, and comorbid variables (Bergmann et al., 2011; Hausheer et al., 2006; Hertz et al., 2012; Kroetz et al., 2010; Schneider et al., 2011; Sissung et al., 2006; Visovsky, Meyer, Roller, & Poppas, 2008; Windebek & Grisold, 2008). However, another important factor influencing the impre
cise understanding regarding the scope of the problem relates

---

**Clinical Journal of Oncology Nursing • Supplement to Volume 17, Number 1 • Management of Taxane-Related Neuropathy**

---

**Clinical Journal of Oncology Nursing • Supplement to Volume 17, Number 1 • Management of Taxane-Related Neuropathy**
<table>
<thead>
<tr>
<th>Study</th>
<th>Sample</th>
<th>Taxane</th>
<th>Dosage</th>
<th>Duration</th>
<th>Sensory Neuropathy (%)</th>
<th>Motor Neuropathy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>Albain et al., 2008</td>
<td>521 previously treated patients with MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>5.7–6.4 cycles (X)</td>
<td>17.7–18.4</td>
<td>3.9–5.3</td>
</tr>
<tr>
<td>Andersson et al., 2011</td>
<td>139 previously treated patients with MBC</td>
<td>Docetaxel</td>
<td>100 mg/m² every three weeks</td>
<td>0–26 cycles</td>
<td>18.7</td>
<td>30.9</td>
</tr>
<tr>
<td>Cassier et al., 2008</td>
<td>107 previously treated patients with MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>4 cycles</td>
<td>6.8° (grade 3 or higher)</td>
<td>6.8° (grade 3 or higher)</td>
</tr>
<tr>
<td></td>
<td>210 previously treated patients with MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>4 cycles</td>
<td>0.9° (grade 3 or higher)</td>
<td>0.9° (grade 3 or higher)</td>
</tr>
<tr>
<td>Eiermann et al., 2011</td>
<td>1,635 patients undergoing adjuvant treatment for MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>6 cycles</td>
<td>Not reported</td>
<td>0.3 (grade 3 or higher)</td>
</tr>
<tr>
<td></td>
<td>1,634 patients undergoing adjuvant treatment for MBC</td>
<td>Docetaxel</td>
<td>100 mg/m² every three weeks</td>
<td>4 cycles</td>
<td>Not reported</td>
<td>1.5 (grade 3 or higher)</td>
</tr>
<tr>
<td>Fountzilas et al., 2009</td>
<td>131 previously treated patients with MBC</td>
<td>Paclitaxel (plus carboplatin)</td>
<td>175 mg/m² every three weeks</td>
<td>6 cycles</td>
<td>5° (grade 3 or higher)</td>
<td>5° (grade 3 or higher)</td>
</tr>
<tr>
<td></td>
<td>134 previously treated patients with MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>6 cycles</td>
<td>0° (grade 3 or higher)</td>
<td>0° (grade 3 or higher)</td>
</tr>
<tr>
<td></td>
<td>133 previously treated patients with MBC</td>
<td>Paclitaxel</td>
<td>80 mg/m² weekly</td>
<td>12 weeks</td>
<td>8° (grade 3 or higher)</td>
<td>8° (grade 3 or higher)</td>
</tr>
<tr>
<td>Frasci et al., 2006</td>
<td>100 patients with locally advanced MBC</td>
<td>Paclitaxel (plus cisplatin)</td>
<td>120 mg/m² weekly</td>
<td>12 weeks</td>
<td>3® (grade 3 or higher)</td>
<td>3® (grade 3 or higher)</td>
</tr>
<tr>
<td></td>
<td>100 patients with locally advanced MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>4 cycles</td>
<td>0® (grade 3 or higher)</td>
<td>0® (grade 3 or higher)</td>
</tr>
<tr>
<td>Gradishar et al., 2005</td>
<td>229 previously treated patients with MBC</td>
<td>nab-Paclitaxel</td>
<td>260 mg/m² every three weeks</td>
<td>56% received 6 cycles or more</td>
<td>Not reported</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>225 previously treated patients with MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>50% received 6 cycles or more</td>
<td>Not reported</td>
<td>2</td>
</tr>
</tbody>
</table>

°Sensory versus motor was not delineated.

°°Sensory and motor signs and symptoms are combined into one scale, rated from 0–4, with a higher score meaning worse neuropathy.

°°°PNQ scores D and E indicate moderate to severe ratings assessed at cycle 7.

MBC—metastatic breast cancer; NCI CTCAE—National Cancer Institute Common Terminology Criteria for Adverse Events; PNQ—Patient Neurotoxicity Questionnaire
<table>
<thead>
<tr>
<th>Study</th>
<th>Sample</th>
<th>Taxane</th>
<th>Dosage</th>
<th>Duration</th>
<th>Sensory Neuropathy (%)</th>
<th>Motor Neuropathy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hamberg et al., 2011</td>
<td>53 previously treated patients with MBC</td>
<td>Docetaxel (plus concurrent trastuzumab)</td>
<td>100 mg/m² every three weeks</td>
<td>6 cycles</td>
<td>62 (grades 1–4); 8 (grade 3 or higher)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>46 previously treated patients with MBC</td>
<td>Docetaxel (following trastuzumab)</td>
<td>100 mg/m² every three weeks</td>
<td>6 cycles</td>
<td>31 (grades 1–4); 0 (grade 3 or higher)</td>
<td>Not reported</td>
</tr>
<tr>
<td>Loesch et al., 2010</td>
<td>906 patients undergoing adjuvant treatment for MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>4 cycles</td>
<td>Not reported</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>895 patients undergoing adjuvant treatment for MBC</td>
<td>Paclitaxel</td>
<td>200 mg/m² every three weeks followed by 80 mg/m² weekly</td>
<td>4 cycles followed by 12 weeks</td>
<td>Not reported</td>
<td>12.7</td>
</tr>
<tr>
<td>Miles et al., 2010</td>
<td>231 previously treated patients with locally advanced or MBC</td>
<td>Docetaxel</td>
<td>100 mg/m² every three weeks</td>
<td>42% received a maximum of 9 cycles</td>
<td>Not reported</td>
<td>2.2 (grade 3 or higher)</td>
</tr>
<tr>
<td>Miller et al., 2007</td>
<td>346 previously treated patients with locally advanced or MBC</td>
<td>Paclitaxel</td>
<td>90 mg/m² weekly for three of four weeks</td>
<td>Not reported</td>
<td>17.1</td>
<td>0.6</td>
</tr>
<tr>
<td>Nielsen et al., 2011</td>
<td>167 previously treated patients with locally advanced or MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>6 cycles (median)</td>
<td>9</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>164 previously treated patients with locally advanced or MBC</td>
<td>Docetaxel</td>
<td>100 mg/m² every three weeks</td>
<td>6 cycles (median)</td>
<td>4.9</td>
<td>6.1</td>
</tr>
<tr>
<td>Nuzzo et al., 2008</td>
<td>48 patients, aged 65–79 year, undergoing adjuvant treatment for MBC</td>
<td>Docetaxel</td>
<td>35 mg/m² weekly three of every four weeks</td>
<td>4–6 cycles</td>
<td>2.1 (4.2 grade 1)</td>
<td>2.1</td>
</tr>
<tr>
<td>Piedbois et al., 2007</td>
<td>35 patients undergoing neoadjuvant treatment for MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>6 cycles</td>
<td>17 (grades 1–4); 0 (grade 3 or higher)</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

* Sensory versus motor was not delineated.
* Sensory and motor signs and symptoms are combined into one scale, rated from 0–4, with a higher score meaning worse neuropathy.
* PNQ scores D and E indicate moderate to severe ratings assessed at cycle 7.

MBC—metastatic breast cancer; NCI CTCAE—National Cancer Institute Common Terminology Criteria for Adverse Events; PNQ—Patient Neurotoxicity Questionnaire

(Continued on the next page)
TABLE 1. Taxane-Induced Peripheral Neuropathy Incidence and Severity in Phase III Clinical Trials (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample</th>
<th>Taxane</th>
<th>Dosage</th>
<th>Duration</th>
<th>Sensory Neuropathy (%)</th>
<th>Motor Neuropathy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>Piedbois et al., 2007</td>
<td>30 and 34 patients (two samples) undergoing neoadjuvant treatment for MBC</td>
<td>Docetaxel</td>
<td>100 mg/m² every two weeks</td>
<td>4 cycles</td>
<td>47–53</td>
<td>9–10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(grade 3 or higher)</td>
<td></td>
</tr>
<tr>
<td>Rivera et al., 2008</td>
<td>59 previously treated patients with locally advanced or MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>9.5 cycles (median)</td>
<td>Not reported</td>
<td>10% (grade 3 or higher)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>59 previously treated patients with locally advanced or MBC</td>
<td>Docetaxel</td>
<td>35 mg/m² weekly every three of four weeks</td>
<td>7 cycles (median)</td>
<td>Not reported</td>
<td>5% (grade 3 or higher)</td>
</tr>
<tr>
<td>Seidman et al., 2008</td>
<td>225 previously treated patients with locally advanced or MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>Not reported (until progression or severe)</td>
<td>21</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>346 previously treated patients with locally advanced or MBC</td>
<td>Paclitaxel</td>
<td>80–100 mg/m² weekly</td>
<td>Not reported (until progression or severe)</td>
<td>21</td>
<td>24–30</td>
</tr>
<tr>
<td>Shimozuma et al., 2012</td>
<td>76 patients undergoing adjuvant treatment for MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>8 cycles</td>
<td>12.3¹ (grade D or higher)</td>
<td>NCI CTCAE or PNQ incidence totals not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>75 patients undergoing adjuvant treatment for MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>8 cycles</td>
<td>14.9¹ (grade D or higher)</td>
<td>NCI CTCAE or PNQ incidence totals not reported</td>
</tr>
<tr>
<td>Untch et al., 2011</td>
<td>362 patients undergoing neoadjuvant treatment for MBC</td>
<td>Paclitaxel</td>
<td>175 mg/m² every three weeks</td>
<td>4 cycles</td>
<td>60.2 (grade 1–4); 2.5 (grade 3 or higher)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>352 patients undergoing neoadjuvant treatment for MBC</td>
<td>Paclitaxel</td>
<td>225 mg/m² every two weeks</td>
<td>3 cycles</td>
<td>81.5 (grades 1–4); 8.9 (grade 3 or higher)</td>
<td>Not reported</td>
</tr>
<tr>
<td>Valero et al., 2011</td>
<td>131 previously treated patients with MBC</td>
<td>Docetaxel</td>
<td>100 mg/m² every three weeks</td>
<td>8 cycles</td>
<td>58 (grades 1–4); 3 (grade 3 or higher)</td>
<td>8.4 (grades 1–4); 0.8 (grade 3 or higher)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>131 previously treated patients with MBC</td>
<td>Docetaxel</td>
<td>75 mg/m² every three weeks</td>
<td>8 cycles</td>
<td>45.8 (grades 1–4); 0.8 (grade 3 or higher)</td>
<td>4.6 (grades 1–4); 0 (grade 3 or higher)</td>
</tr>
</tbody>
</table>

¹ Sensory versus motor was not delineated.
² Sensory and motor signs and symptoms are combined into one scale, rated from 0–4, with a higher score meaning worse neuropathy.
³ PNQ scores D and E indicate moderate to severe ratings assessed at cycle 7.

MBC—metastatic breast cancer; NCI CTCAE—National Cancer Institute Common Terminology Criteria for Adverse Events; PNQ—Patient Neurotoxicity Questionnaire
to inadequate attention to TIPN measurement. Many clinicians believe that TIPN poses only a minor problem because, in most published reports, only the rates of moderate and severe (grades 3 or 4) TIPN are reported. The reporting patterns illustrate clinician bias regarding the degree of clinically important TIPN and discount the discomfort and distress potentially caused by any degree of peripheral neuropathy.

Another problem is that, in phase III studies, TIPN is most often quantified using toxicity grading scales, and these scales are known to have suboptimal reliability and validity as well as suboptimal sensitivity reflected by floor effects (low scores), leading to underrepresentation of TIPN incidence and severity (Cavaletti et al., 2010; Griffith et al., 2010; Kuroi et al., 2009; Postma et al., 1998). To illustrate the main limitations, grading of two patient examples is described here.

Clinical Examples

The first patient has reduced ankle reflexes as the only sign of peripheral neuropathy. The second patient reports paresthesias that do not interfere with activity, plus all reflexes are absent. Per NCI CTCAE, version 4, paresthesias and tendon reflex loss define grade 1 sensory neuropathy, and grades 2–4 are defined by moderate, severe, and life-threatening interference with activities of daily living. Grade 5 equates to death from peripheral neuropathy, an extremely rare event. Both patients have grade 1 TIPN according to the NCI CTCAE, but the second patient’s neuropathy is more severe. This example illustrates the lack of sensitivity associated with the NCI CTCAE grading system because signs and symptoms representing a broad range of TIPN severity each fall within the same low-scoring category and very few patients receive the highest score.

To illustrate another grading scale limitation, consider how several different oncology providers might define moderate, severe, and life-threatening neuropathy. Because no operational definitions are provided for the various grades, each provider may define these grades differently, leading to lack of consistency and poor reliability across providers.

Based on these examples, it is easy to see why grading scales are problematic. However, grading scale use is deeply embedded within clinical and research practice. Mounting evidence supports the stance that grading scales should no longer be used or, at the very least, should be used alongside other patient-reported outcome measures (Atkinson et al., 2011; Basch et al., 2009; Kuroi et al., 2009; Shimozuma et al., 2009; Sloan et al., 2007). Shimozuma et al. (2009) compared several validated patient-reported outcome measure scores with provider-obtained NCI CTCAE scores and found that TIPN was consistently reported to be more prevalent and severe when quantified using patient-reported outcome measures. In another large cooperative group study in which 696 patients received oxaliplatin for colorectal cancer, neuropathy was quantified using both the NCI CTCAE and a patient-reported numeric rating scale (NRS) (Goldberg et al., 2004). In that study, neuropathy onset was detected several months sooner when the NRS was used versus the NCI CTCAE, allowing timelier oxaliplatin dose modifications (Morton et al., 2005; Sloan et al., 2007). This evidence supports the position that patient-reported outcome measures should be integrated into clinical trials because grading scales alone do not adequately quantify dose-limiting adverse events.

Table 2 provides a summary of selected TIPN measures that have been tested in patients receiving taxanes. In addition, two reviews (Cavaletti et al., 2010; Griffith et al., 2010) have
### TABLE 2. Peripheral Neuropathy Measurement Tools Tested in Patients Receiving Taxanes

<table>
<thead>
<tr>
<th>Measure</th>
<th>Type</th>
<th>Sample</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy-Induced Peripheral Neuropathy Tool (Toft Hansen et al., 2011)</td>
<td>Subjective; patient reported</td>
<td>Mixed population of patients with cancer and neurotoxic agents</td>
<td>The Chemotherapy-Induced Peripheral Neuropathy Tool is a 50-item self-report questionnaire that measures interference with daily activities (14 items) and the presence, severity, distress, and frequency of nine peripheral neuropathy symptoms (cold sensitivity, muscle and joint aches, numbness and tingling in hands and feet, loss of balance, weakness, and nerve pain) based on an 11-point scale (36 items). Satisfactory reliability and validity have been demonstrated; sensitivity to change and clinical use have not been evaluated. The length of this instrument makes it less feasible for use in busy clinical settings.</td>
</tr>
<tr>
<td>FACT/GOG-Ntx subscale (Calhoun et al., 2003; Cavaletti et al., 2010; Griffith et al., 2010; Huang et al., 2007)</td>
<td>Subjective; patient reported</td>
<td>Patients with cancer receiving carboplatin and paclitaxel</td>
<td>The FACT/GOG-Ntx is an 11-item neurotoxicity subscale of the FACT-General scale, assessing sensory, motor, and auditory function. Items are scored from 0 (not at all) to 4 (very much). Hand and feet symptoms are assessed separately, a potential advantage of this instrument. One weakness is that the two auditory items are not relevant to TIPN. Satisfactory reliability and validity have been demonstrated. The FACT/GOG-Ntx is short and can be easily administered to patients by nurses working in busy clinical settings.</td>
</tr>
<tr>
<td>Patient Neurotoxicity Questionnaire (Shimozuma et al., 2009)</td>
<td>Subjective; patient reported</td>
<td>Patients with cancer receiving taxanes</td>
<td>Contains two subjective items that assess sensory and motor neuropathy, which are graded from A (no neuropathy) to E (severe neuropathy). Interference with daily activities is used to differentiate between mild versus moderately severe and severe symptoms. Hand and feet symptoms are assessed together, a potential limitation of the measure. The terms &quot;mild&quot; and &quot;moderate&quot; are not linked with operational definitions, potentially leading to suboptimal reliability. As such, satisfactory validity has been demonstrated, but reliability data are not available. Interpretation of a numeric versus alphabetic rating scale may be more intuitive for patients and clinicians. This measure would be easy for nurses to administer to patients, but instrument reliability should be tested before being mainstreamed into clinical practice.</td>
</tr>
<tr>
<td>Peripheral Neuropathy Scale (Almadrones et al., 2004)</td>
<td>Subjective; patient reported</td>
<td>Patients with cancer receiving cisplatin and paclitaxel</td>
<td>The Peripheral Neuropathy Scale is a tool that combines an eight-item functional status scale with an 11-item neuropathy scale. Items from the scale were later revised and became the basis for the FACT/GOG-Ntx subscale.</td>
</tr>
<tr>
<td>QLQ-CIPN20 (Postma et al., 2005)</td>
<td>Subjective; patient reported</td>
<td>Mixed population of patients with cancer and neurotoxic agents</td>
<td>The QLQ-CIPN20 is a 20-item self-report questionnaire designed to supplement the EORTC quality-of-life questionnaire. The QLQ-CIPN20 contains nine items that assess sensory function, eight items that assess motor function, and three items that assess autonomic function. The extent to which patients experience neuropathy symptoms and associated functional limitations are scored from 1 (not at all) to 4 (very much). Hand and feet symptoms are assessed separately, a potential advantage of this instrument. Only internal consistency reliability testing has been reported. Additional psychometric testing is warranted before this instrument can be used in routine practice.</td>
</tr>
<tr>
<td>TNS (full) (Cavaletti et al., 2006, 2010; Chaudhry et al., 1994; Cornblath et al., 1999; Griffith et al., 2010; Smith et al., 2008)</td>
<td>Subjective/objective; provider reported based on history and physical examination</td>
<td>Mixed population of patients with cancer receiving neurotoxic agents</td>
<td>The TNS is a composite instrument that facilitates objective scoring of peripheral neuropathy signs and symptoms. Items include pinprick sensation; vibration sensation using a 128 Hz tuning fork; quantitative sensory testing of vibration and temperature sensation; sensory and motor nerve conduction study findings; tendon reflexes; strength; patient-reported numbness, tingling, and neuropathic pain distal to proximal extension; and motor and autonomic symptoms. All items are scored from 0 (no neuropathy) to 4 (severe neuropathy). Item scores are added together to comprise a total score. Satisfactory reliability and validity have been demonstrated.</td>
</tr>
<tr>
<td>TNS (shortened version) (Griffith et al., 2010; Lavioie Smith et al., 2011; Smith et al., 2010)</td>
<td>Subjective/objective; provider reported based on history and physical examination</td>
<td>Patients with cancer receiving taxanes and platinums</td>
<td>The shortened TNS includes the following items: patient-reported numbness, tingling, and neuropathic pain distal to proximal extension; vibration sensation using a 128-Hz tuning fork; and tendon reflexes. All items are scored from 0 (no neuropathy) to 4 (severe neuropathy). Item scores are added together to comprise a total score. Satisfactory reliability and validity have been demonstrated, and assessments can be obtained by nurses in about five minutes.</td>
</tr>
</tbody>
</table>

ECOG—Eastern Cooperative Oncology Group; EORTC—European Organisation for the Research and Treatment of Cancer; FACT/GOG-Ntx—Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity; NCI CTCAE—National Cancer Institute’s Common Terminology Criteria for Adverse Events; QLQ-CIPN20—Quality of Life Questionnaire—Chemotherapy-Induced Peripheral Neuropathy 20; TIPN—taxane-induced peripheral neuropathy; TNS—Total Neuropathy Score; WHO—World Health Organization
TABLE 2. Peripheral Neuropathy Measurement Tools Tested in Patients Receiving Taxanes (Continued)

<table>
<thead>
<tr>
<th>Measure</th>
<th>Type</th>
<th>Sample</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCI CTCAE, ECOG, Ajani, WHO (Cavaletti et al., 2010; Griffeth et al., 2010; Postma et al., 1998)</td>
<td>Clinician reported</td>
<td>Mixed population of patients with cancer receiving neurotoxic agents</td>
<td>The scales guide gross assessment of neurotoxicity through a combination of subjective and objective parameters. Toxicity is graded from 0–4/5, with higher numbers representing worse neuropathy. The scoring criteria used in the various grading scales and versions are not consistent across scales. Terms such as &quot;mild,&quot; &quot;moderate,&quot; and &quot;severe&quot; are used without commonly accepted definitions. Grading-scale floor effects and suboptimal reliability, validity, and sensitivity have been reported.</td>
</tr>
</tbody>
</table>

ECOG—Eastern Cooperative Oncology Group; EORTC—European Organisation for the Research and Treatment of Cancer; FACT/GOG-Ntx—Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity; NCI CTCAE National Cancer Institute’s Common Terminology Criteria for Adverse Events; QLQ-CIPN20—Quality of Life Questionnaire—Chemotherapy-Induced Peripheral Neuropathy 20; TIPN—taxane-induced peripheral neuropathy; TNS—Total Neuropathy Score; WHO—World Health Organization

summarized the available literature regarding the development of instruments to measure chemotherapy-induced peripheral neuropathy. Griffeth et al. (2010) used a meticulous process to identify and evaluate published research and recommended two measures for future use: the FACT/GOG-Ntx (Calhoun et al., 2003) and a shortened version of the TNS (Chaudhry et al., 1994; Cornblath et al., 1999; Griffeth et al., 2010; Lavoie Smith et al., 2011; Smith et al., 2010). Several advantages in routinely assessing TIPN using those two measures exist. First, the measures have undergone more extensive testing in patients with TIPN compared with other measures and have been shown to have strong psychometric properties. This combined subjective/objective measurement approach will enhance the understanding of TIPN prevalence and severity because subtle differences in TIPN will be more detectable and patients (not physicians or nurses) will have an opportunity to describe their symptoms and related functional limitations.

In addition to being reliable and valid, the FACT/GOG-Ntx and the shortened TNS instruments are relatively easy to use. The FACT/GOG-Ntx subscale consists of only 11 items and can be given to patients to complete while they wait to receive each taxane treatment. The form is written at a sixth-grade reading level and takes only a few minutes to complete (Calhoun et al., 2003). Table 3 provides information regarding the TNS scoring criteria (modified). Clinicians would likely need to keep these criteria nearby; however, this should not be a barrier to its use because many clinicians also need to frequently refer to the NCI CTCAE scoring criteria when grading neuropathy and a variety of other adverse events. The shortened TNS has been shown to be feasible for use by advanced practice nurses, and an ongoing study has demonstrated that staff nurses are capable of using the TNS when measuring vincristine-induced neuropathy in children with leukemia (Smith, Renbarger, et al., 2012). With the shortened version, a TNS-based assessment can be completed in about five minutes. Subjective numbness, tingling, and neuropathic pain scores are obtained by asking the patient to describe the distal to proximal extension of these symptoms. For example, a nurse would ask the patient whether his or her symptoms are present only in the toes or if they extend further up the foot to the ankle and beyond. More severe TIPN is associated with greater proximal extension of symptoms. Hand symptoms typically appear after feet symptoms have already

| TABLE 3. Shortened and Revised Total Neuropathy Scoring Criteria |
|-------------------|-----|----------------|------------------|-----------------|-----------------|
| Item              | 0   | 1              | 2               | 3               | 4               |
| Symptom extension (tingling) None | Symptoms from toes to midfoot (not including heel) | Symptoms from midfoot to ankle | Symptoms extend above ankle to knee without upper extremity symptoms | Symptoms above knee or concurrent lower and upper extremity symptoms |
| Symptom extension (numbness) None | Symptoms from toes to midfoot (not including heel) | Symptoms from midfoot to ankle | Symptoms extend above ankle to knee without upper extremity symptoms | Symptoms above knee or concurrent lower and upper extremity symptoms |
| Symptom extension (neuropathic pain) None | Symptoms from toes to midfoot (not including heel) | Symptoms from midfoot to ankle | Symptoms extend above ankle to knee without upper extremity symptoms | Symptoms above knee or concurrent lower and upper extremity symptoms |
| Tendon reflexes Normal | Ankle reflex absent | Ankle reflex absent or others reduced | All reflexes absent |
| Vibration sensibility Normal | Absent or decreased from toes to midfoot (not including heel) | Absent or decreased from midfoot to ankle | Absent or decreased above ankle to knee |

Note. Based on information from Chaudhry et al., 1994; Cornblath et al., 1999; Lavoie Smith et al., 2011; Smith et al., 2008, 2010.
developed because the upper extremity nerve fibers are more proximal to the spinal cord. One limitation of the TNS scoring criteria is that symptom severity cannot be adequately assessed. Therefore, use of a 0–10 NRS should be considered, particularly when assessing neuropathic pain severity (Lavoie Smith et al., 2009; Smith et al., 2008).

The most difficult aspect of performing the TNS-based assessment is learning how to obtain tendon reflex scores; however, if nurses need assistance, they can seek it from an experienced nurse practitioner or physician colleagues. Reflex assessment provides a measure of both motor and sensory function. The Achilles reflex should be tested first; if the reflex is diminished or absent, other reflexes should be assessed, such as patellar, brachioradialis, biceps, and triceps. However, if the Achilles reflex is normal, no additional reflex testing is needed. If asymmetrical findings are discovered (for any TNS item), the most severe finding is used for scoring.

Gaining competence in assessing vibration sensibility testing using a basic 128 Hz weighted tuning fork is not difficult, and nurses and patients seem to enjoy conducting and undergoing these assessments, respectively. The tuning fork should be firmly tapped on the palm of the hand to initiate vibration. The vibrating tuning fork is first placed on the interphalangeal joint of the great toe (see Figure 1A). The nurse places a finger under the patient’s toe to compare the patient’s vibration sensibility with the nurse’s (control). The nurse should feel the vibration through the patient’s toe for at least as long as the patient. The patient is instructed to report when vibration is no longer detected. If the patient feels the vibration longer than the nurse, this is defined as normal. If vibration sensation is normal at the great toe, it will be normal elsewhere (more proximally), and additional assessments are not needed. However, if vibration sensation is diminished or absent in the great toe, the nurse then conducts the testing at the middorsal foot and medial malleolus (ankle) areas (see Figures 1B and 1C), followed by the midfibular and patellar regions (see Figures 1D and 1E). Upper extremity vibration sensibility is first tested at the distal interphalangeal joint of the index finger (see Figure 2A) and then the ulnar styloid (wrist) (see Figure 2B) and lateral epicondyle (elbow) (see Figure 2C). Once the patient is no longer able to sense vibration, the nurse determines whether vibration was still detectable by quickly moving the tuning fork to his or her own ankle, knee, or wrist. However, one limitation is that nurses with impaired vibration sensation are less able to obtain valid scores. An alternative approach is to record how long (in seconds) the patient feels the vibration. Feeling the vibration for about 15 seconds is considered to be normal for all testing locations except for the patella (10 seconds) and index finger (25 seconds) (Ohsumi & Sunada, 2004). Variability will exist based on how hard the tuning fork is tapped. A specialized tuning fork (Rydel-Seiffer) is available to facilitate vibration assessment, but these generally are not available in oncology clinical settings (Pestronk et al., 2004). Although this low-tech approach to vibration assessment is imperfect, it has been shown to be reliable, valid, and more sensitive to change over time than grading scale scoring (Lavoie Smith et al., 2011; Smith, Renbarger, et al., 2012).

FIGURE 1. Performing a Vibration Sensibility Test of the Lower Extremities

Note. Photos courtesy of Josh Weiland Photography. Used with permission.

Treating Taxane-Induced Peripheral Neuropathy

Despite escalating attempts to find effective treatments for TIPN, little progress has been made (Pachman, Barton, Watson, & Loprinzi, 2011; Visovsky, Collins, Abbott, Aschenbrenner, & Hart, 2007; Wolf, Barton, Kottschade, Grothey, & Loprinzi, 2008). Ineffective drugs for treating TIPN include amitriptyline (Kautio et al., 2009), gabapentin (Rao et al., 2007), and lamotrigine (Rao et al., 2008). Barton et al. (2011) tested the efficacy of topical baclofen, amitriptyline, and ketamine (BAK) gel. The researchers reported that BAK was only marginally effective, possibly because of subtherapeutic dosing. One phase III trial testing the efficacy of acetyl-L-carnitine revealed unexpected findings in that the drug worsened TIPN symptoms compared with placebo (Hershman et al., 2012). Positive findings came from a large, phase III placebo-controlled study conducted by...
the Cancer and Leukemia Group B, which demonstrated that oral duloxetine 60 mg daily was effective in diminishing taxane-related painful neuropathy (Smith, Pang, et al., 2012). With only one positive phase III trial to date, continued research examining new interventions to prevent or diminish TIPN is needed.

Nurses can play a role in diminishing some of the negative consequences of TIPN by educating patients on the importance of reporting symptoms. By encouraging patients to report their symptoms and taking a more active role in TIPN assessment, nurses can help ensure that taxane treatment is modified sooner. Impaired foot and hand sensation places patients at increased risk for mechanical or thermal injury. Nurses should counsel patients regarding strategies to minimize injury risk. Such strategies include turning down the temperature settings on home water heaters, using gloves when washing dishes or gardening, and always wearing shoes with soles, particularly when outdoors. Tofthagen, Overcash, and Kip (2012) reported that patients receiving taxanes may be more likely to fall than those receiving platinum drugs, and that a higher cumulative chemotherapy dose, impaired balance, muscle weakness, more severe TIPN symptoms, and impaired walking and driving ability are predictive of increased fall risk. Nurses should advise patients who are at high risk for tripping or falling to remove clutter and scatter rugs in their homes. Because patients with TIPN need to rely more heavily on visual clues when monitoring the location of their feet on the ground, patients should avoid walking in poorly lighted areas. A referral to an occupational or physical therapist may be necessary in cases of severely impaired balance, foot drop, or extremity weakness. Adaptive equipment, such as large-handled eating utensils, foot braces, walkers, or canes can be helpful to optimize functional capacity and safety. In addition, muscle-strengthening exercises may help to minimize weakness. Patients with severely impaired plantar foot sensation or foot drop should be advised not to drive. Lastly, because orthostatic hypotension can occur because of autonomic neuropathy, nurses should teach patients to change positions slowly so as to avoid syncopal episodes.

**Future Research**

Studies are beginning to suggest that taxane neurotoxicity may be directly related to individual variations in neurotoxic drug metabolism, distribution, and elimination; however, the results, to date, are inconclusive (Bergmann et al., 2011; Sissung et al., 2006). Three large studies have identified genetic polymorphisms associated with TIPN (Hertz et al., 2012; Kroetz et al., 2010; Schneider et al., 2011). If detection of genetic predictors becomes the standard of care, this could lead to a significant paradigm shift in how TIPN is managed. Patients determined to be at high risk via a genetic test performed prior to receiving taxane therapy might be offered alternative treatments or altered dosing schedules. As one example, it may be possible to individualize taxane dosing so that those with genetic polymorphisms leading to more efficient taxane metabolism would receive higher doses, whereas slow metabolizers would receive lower doses. That approach could ultimately result in improved taxane efficacy while minimizing severe and disabling peripheral neuropathy for long-term cancer survivors.

**Conclusion**

TIPN is an underrecognized problem that significantly compromises quality of life for patients with breast cancer. TIPN is underrecognized because of continued reliance on suboptimal assessment approaches. Emerging empirical evidence suggests that more reliable, valid, sensitive, and clinically feasible TIPN measurement approaches should be used to quantify TIPN in clinical and research settings. However, implementing practice change based on this evidence continues to be challenging. This article provides practical suggestions for how nurses can take the lead in improving TIPN measurement practices. In addition, the search must continue for effective interventions that will ameliorate or even prevent distressing and disabling TIPN symptoms for breast cancer survivors receiving taxane therapy.

**Implications for Practice**

- Taxane-induced peripheral neuropathy should be quantified by determination of the distal to proximal extension of numbness, tingling, and neuropathic pain, as well as vibration sensibility and tendon reflexes.
- Neuropathic pain severity should be assessed using a 0–10 numeric rating scale.
- Validated assessment tools should be administered to patients prior to each taxane treatment.

**FIGURE 2. Performing a Vibration Sensibility Test of the Upper Extremities**

*Note. The tuning fork is firmly tapped on the palm and then placed at the distal interphalangeal joint of the index finger (2A), the ulnar styloid (2B), and the lateral epicondyle (2C).*

*Note. Photos courtesy of Josh Weiland Photography. Used with permission.*
References


Hershman, D.L., Unger, J.M., Crew, K.D., Moinpour, C., Minasian, L.M., 32
Hansen, L., . . . Albain, K.S. (2012). SWOG S0715: Randomized place-
bo-controlled trial of acetyl-L-carnitine for the prevention of taxane-
induced neuropathy during adjuvant breast cancer therapy [Ab-
www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confdId=11&abstractId=95515
Hertz, D.L., Dees, E.C., Motssinger-Reif, A.A., Drobish, A., Roy, S.,
phisms in drug metabolism or transport genes and peripheral
neuropathy during paclitaxel treatment [Abstract 10515]. Journal
ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&con-
fdId=114&abstractId=98689
and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-
induced neurologic symptoms: A Gynecologic Oncology Group
Kauto, A.L., Haanpää, M., Lemenen, A., Kalso, E., Kautiainen, H.,
Kroetz, D.L., Baldwin, R.M., Owzar, K., Jiang, C., Zembutsu,
tion in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced
peripheral neuropathy (PN): Results from a genome-wide
association study (GWAS) in CALGB 40101 [Abstract 3021].
asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confdId=7&abstractId=49598
Kuroi, K., & Shimozuma, K. (2004). Neurotoxicity of taxanes:
Symptoms and quality of life assessment. Breast Cancer, 11,
92–99. doi:10.1007/BF02906810
Kuroi, K., Shimozuma, K., Ohashi, Y., Hisamatsu, K., Masuda, N.,
of chemotherapy-induced peripheral neuropathy due to weekly
paclitaxel in patients with advanced or metastatic breast cancer
(CSP-HOR 02 study). Supportive Care in Cancer, 17, 1071–1080.
Lavioe Smith, E.M., Bakitas, M.A., Homel, P., Fadul, C., Meyer, L.,
methodology to improve neuropathic pain screening and as-
essment in patients with cancer. Journal of Cancer Education,
24, 135–140.
The validity of neuropathy and neuropathic pain measures in patients
with cancer receiving taxanes and platinum. Oncology Nursing
Forum, 38, 133–142. doi:10.1188/11.ONF.133-142
Loesch, D., Greco, F.A., Senzer, N.N., Burris, H.A., Hainsworth,
J.D., Jones, S., . . . Robert, N. (2010). Phase III multicenter trial of
doxorubicin plus cyclophosphamide followed by paclitaxel
compared with doxorubicin plus paclitaxel followed by weekly
paclitaxel as adjuvant therapy for women with high-risk breast
Loprinzi, C.L., Reeves, B.N., Dakhil, S.R., Sloan, J.A., Wolf, S.L.,
taxel-associated acute pain syndrome: Prospective cohort study
Miles, D.W., Chan, A., Dirix, L.Y., Cortes, J., Pivot, X., Tomeczak, P.,
compared with placebo plus docetaxel for the first-line treatment
of human epidermal growth factor receptor 2-negative metastatic
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A.,
. . . Davidson, N.E. (2007). Paclitaxel plus bevacizumab versus pac-
litaxel alone for metastatic breast cancer. New England Journal of
Medicine, 357, 2666–2676. doi:10.1056/NEJMoa072113
Morton, R.F., Sloan, J.A., Grothey, A., Sargent, D.J., McLeod, H.,
single-item measures and the common toxicity criteria in
detecting the onset of oxaliplatin-induced peripheral neu-
ropathy in patients with colorectal cancer [Abstract 8087].
asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confdId=34&abstractId=32577
Nielsen, D.L., Bjerre, K.D., Jakobsen, E.H., Cold, S., Stenbygaard,
docetaxel versus docetaxel in patients with predominantly human
epidermal growth factor receptor 2-negative locally advanced
or metastatic breast cancer. Journal of Clinical Oncology, 29,
4748–4754. doi:10.1200/JCO.2010.33.9507
Nuzzo, F., Morabito, A., De Maio, E., Di Rella, F., Gravina, A., Labo-
adjuvant chemotherapy for elderly breast cancer patients: Safety
data from the multicentre phase 3 randomised ELDA trial. Criti-
Ohsumi, S., & Sunada, Y. (2004). Techniques for the neurological ex-
Chemotherapy-induced peripheral neuropathy: Prevention and
Pestronk, A., Florence, J., Levine, T., Al-Lozi, M., Lopate, G., Miller,
tuning fork: Rapid, sensitive, and predictive of SNAP amplitude.
Peters, C.M., Jimenez-Andrade, J.M., Jonas, B.M., Sevck, M.A.,
paclitaxel administration in the rat induces a peripheral sensory
neuropathy characterized by macrophage infiltration and injury
to sensory neurons and their supporting cells. Experimental
Piedbois, P., Serin, D., Priou, F., Laplaige, P., Greget, S., Angellier,
node-positive breast cancer: Docetaxel followed by epirubicin/
cyclophosphamide (T/EC), or the reverse sequence (EC/T), ev-
ery 2 weeks, versus docetaxel, epirubicin and cyclophosphamide
(TEC) every 3 weeks. AERO B03 randomized phase II study.
painful peripheral neuropathy in the rat produced by the che-
Postma, T.J., Aaronson, N.K., Heimans, J.J., Muller, M.J., Hildebrand,
The development of an EORTC quality of life questionnaire to
assess chemotherapy-induced peripheral neuropathy: The QLQ-
Postma, T.J., Heimans, J.J., Muller, M.J., Ossenkoppele, G.J., Ver-
ity of chemotherapy-induced peripheral neuropathy. Annals of Oncology, 9, 739–744.
Rao, R.D., Flynn, P.J., Sloan, J.A., Wong, G.Y., Novotny, P., Johnson,
management of taxane-induced peripheral neuropathy: A phase 3
randomized, double-blind, placebo-controlled trial, N01C3.


